-
Je něco špatně v tomto záznamu ?
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
G. Giovannoni, R. Gold, K. Selmaj, E. Havrdova, X. Montalban, EW. Radue, D. Stefoski, M. McNeill, L. Amaravadi, M. Sweetser, J. Elkins, G. O'Neill, . ,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
Nursing & Allied Health Database (ProQuest) od 2002-05-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-05-01 do Před 2 měsíci
Psychology Database (ProQuest) od 2002-05-01 do Před 2 měsíci
Odkazy
PubMed
24656609
DOI
10.1016/s1474-4422(14)70039-0
Knihovny.cz E-zdroje
- MeSH
- časové faktory MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- humanizované monoklonální protilátky terapeutické užití MeSH
- imunoglobulin G terapeutické užití MeSH
- imunosupresiva terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- následné studie MeSH
- relabující-remitující roztroušená skleróza farmakoterapie patologie MeSH
- výsledek terapie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze II MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received daclizumab high-yield process (HYP) for 52 weeks. The primary aim of the SELECTION extension study was to assess the safety and immunogenicity of extended treatment with daclizumab HYP. METHODS: A multicentre, randomised, double-blind, 52-week extension trial was done in 74 centres in the Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, and the UK between Feb 13, 2009, and Oct 3, 2012. Eligible patients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had completed the SELECT study. Patients who received placebo in SELECT were randomly assigned (1:1) to receive 150 mg or 300 mg subcutaneous daclizumab HYP every 4 weeks for 52 weeks (treatment initiation group); those who had received daclizumab HYP were randomly assigned (1:1) to continue their present dose with (washout and re-initiation group) or without (continuous treatment group) a washout period of 20 weeks. All randomisation was done with a centralised, interactive voice-response system. Patients and personnel were masked to treatment assignment, except for the site pharmacist who prepared the study drug but had no interaction with patients. The primary endpoints were the safety and immunogenicity of daclizumab HYP. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00870740. FINDINGS: 517 (91%) of 567 patients who completed the SELECT trial entered SELECTION, of whom 170 were in the treatment initiation group, 173 in the continuous treatment group, and 174 in the washout and re-initiation group. 11 patients in the treatment initiation group (6%), 13 in the continuous treatment group (8%), and ten in the washout and re-initiation group (6%) had any serious adverse event other than relapse of multiple sclerosis. One patient in the washout and re-initiation group (300 mg daclizumab HYP) died because of autoimmune hepatitis; a contributory role of daclizumab HYP could not be excluded. Seven patients tested positive for neutralising antidrug antibodies: one (1%) of 128 for whom data were available in the continuous treatment group (this patient also tested positive at SELECTION baseline), four (2%) in the treatment initiation group, and two (2%) of 129 in the washout and re-initiation group. INTERPRETATION: Adverse events and immunogenicity were not increased in the second year of continuous treatment with daclizumab HYP or during treatment washout and re-initiation. These results support further assessment of daclizumab HYP for relapsing-remitting multiple sclerosis. FUNDING: Biogen Idec and AbbVie Biotherapeutics.
Charles University Prague Prague Czech Republic
Medical University of Lodz Lodz Poland
Rush University Medical Center Chicago IL USA
St Josef Hospital Ruhr University Bochum Bochum Germany
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14063678
- 003
- CZ-PrNML
- 005
- 20140710092926.0
- 007
- ta
- 008
- 140704s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1474-4422(14)70039-0 $2 doi
- 035 __
- $a (PubMed)24656609
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Giovannoni, Gavin $u Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Electronic address: g.giovannoni@qmul.ac.uk.
- 245 10
- $a Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial / $c G. Giovannoni, R. Gold, K. Selmaj, E. Havrdova, X. Montalban, EW. Radue, D. Stefoski, M. McNeill, L. Amaravadi, M. Sweetser, J. Elkins, G. O'Neill, . ,
- 520 9_
- $a BACKGROUND: In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received daclizumab high-yield process (HYP) for 52 weeks. The primary aim of the SELECTION extension study was to assess the safety and immunogenicity of extended treatment with daclizumab HYP. METHODS: A multicentre, randomised, double-blind, 52-week extension trial was done in 74 centres in the Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, and the UK between Feb 13, 2009, and Oct 3, 2012. Eligible patients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had completed the SELECT study. Patients who received placebo in SELECT were randomly assigned (1:1) to receive 150 mg or 300 mg subcutaneous daclizumab HYP every 4 weeks for 52 weeks (treatment initiation group); those who had received daclizumab HYP were randomly assigned (1:1) to continue their present dose with (washout and re-initiation group) or without (continuous treatment group) a washout period of 20 weeks. All randomisation was done with a centralised, interactive voice-response system. Patients and personnel were masked to treatment assignment, except for the site pharmacist who prepared the study drug but had no interaction with patients. The primary endpoints were the safety and immunogenicity of daclizumab HYP. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00870740. FINDINGS: 517 (91%) of 567 patients who completed the SELECT trial entered SELECTION, of whom 170 were in the treatment initiation group, 173 in the continuous treatment group, and 174 in the washout and re-initiation group. 11 patients in the treatment initiation group (6%), 13 in the continuous treatment group (8%), and ten in the washout and re-initiation group (6%) had any serious adverse event other than relapse of multiple sclerosis. One patient in the washout and re-initiation group (300 mg daclizumab HYP) died because of autoimmune hepatitis; a contributory role of daclizumab HYP could not be excluded. Seven patients tested positive for neutralising antidrug antibodies: one (1%) of 128 for whom data were available in the continuous treatment group (this patient also tested positive at SELECTION baseline), four (2%) in the treatment initiation group, and two (2%) of 129 in the washout and re-initiation group. INTERPRETATION: Adverse events and immunogenicity were not increased in the second year of continuous treatment with daclizumab HYP or during treatment washout and re-initiation. These results support further assessment of daclizumab HYP for relapsing-remitting multiple sclerosis. FUNDING: Biogen Idec and AbbVie Biotherapeutics.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobulin G $x terapeutické užití $7 D007074
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $x patologie $7 D020529
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a klinické zkoušky, fáze II $7 D017427
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gold, Ralf $u St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
- 700 1_
- $a Selmaj, Krzysztof $u Medical University of Lodz, Lodz, Poland.
- 700 1_
- $a Havrdova, Eva $u Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Montalban, Xavier $u Vall d'Hebron University Hospital, Barcelona, Spain.
- 700 1_
- $a Radue, Ernst-Wilhelm $u University Hospital Basel, Basel, Switzerland.
- 700 1_
- $a Stefoski, Dusan $u Rush University Medical Center, Chicago, IL, USA.
- 700 1_
- $a McNeill, Manjit $u Biogen Idec, Cambridge, MA, USA.
- 700 1_
- $a Amaravadi, Lakshmi $u Biogen Idec, Cambridge, MA, USA. $7 gn_A_00005276
- 700 1_
- $a Sweetser, Marianne $u Biogen Idec, Cambridge, MA, USA.
- 700 1_
- $a Elkins, Jacob $u Biogen Idec, Cambridge, MA, USA.
- 700 1_
- $a O'Neill, Gilmore $u Biogen Idec, Cambridge, MA, USA.
- 700 1_
- $a ,
- 773 0_
- $w MED00006921 $t Lancet neurology $x 1474-4465 $g Roč. 13, č. 5 (2014), s. 472-81
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24656609 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140710093218 $b ABA008
- 999 __
- $a ok $b bmc $g 1031162 $s 862410
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 13 $c 5 $d 472-81 $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921
- LZP __
- $a Pubmed-20140704